Davion Healthcare Plc Appoints Vienna Capital Partners to Support US$100 Million Acquisition Financing Strategy

The financing objective covers multiple acquisitions, but no binding lender commitments have been secured under the proposed program.

Rhea-AI Summary

Davion Healthcare (NASDAQ: DAVI) appointed Vienna Capital Partners to support its proposed US$100 million-plus acquisition financing strategy for 2027.

The non-exclusive advisory agreement covers financing structures and potential funding arrangements. Davion’s initial aggregate target is US$100 million, potentially increasing as its program develops. The company intends to pursue multiple acquisitions of established, profitable, cash-generative businesses, principally in the United States, and prefers senior secured, non-convertible debt to limit equity dilution. The appointment follows its proposed $13.5 million acquisition of Healthcare Stat Homecare.

The target is indicative, not an available credit facility; no binding lender commitments have been secured. Financing remains subject to lender approval, satisfactory due diligence and definitive documentation.

5 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Acquisition financing objective targets an initial US$100 million for multiple acquisitions during 2027, potentially increasing as the program develops. 3.1× market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed $13.5 million Healthcare Stat Homecare acquisition targets a profitable US home healthcare business. 41% of market cap
• Minor pointVienna Capital Partners appointment provides non-exclusive advice on institutional financing structures and potential funding arrangements.
• Minor pointDavion prefers senior secured, non-convertible debt with the objective of limiting equity dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.Acquisition plans focus principally on US businesses with established operations, sustainable revenues and positive cash flow.

Negative

• Moderate pointNo binding lender commitments have been secured; the financing target is not an established or available credit facility.
• Minor point. Forward-looking: it has not happened yet and may not happen.Future financing requires lender approval, satisfactory due diligence and definitive documentation, alongside applicable conditions.

Key Figures

Initial financing objective: US$100 million

Initial financing objective

US$100 million

Indicative aggregate target for 2027; not a committed or currently available credit facility

Previous Acquisition Reports

1 past event · Latest: Oct 29

Same Type 1 event

1. Oct 29

   Acquisition agreement

   24h Move

   -18.2%

   Agreed to buy a profitable US homecare business for $13.5 million, with cash-and-share consideration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

senior secured, non-convertible debt financing, equity dilution, credit facility, +1 more

5 terms

senior secured financial

"senior secured, non-convertible debt financing"

Senior secured describes a loan or bond that has first claim on a company’s assets and is backed by specific collateral, like a mortgage on property. For investors, that means they are paid before other creditors if the company struggles or is liquidated, reducing the chance of loss compared with unsecured or junior debt. Think of it as a front-of-the-line, collateral-backed claim that typically carries lower interest because of that added protection.

non-convertible debt financing financial

"senior secured, non-convertible debt financing"

Non-convertible debt financing is when a company raises money by borrowing through bonds or loans that cannot be turned into shares of the company. For investors, it matters because this keeps existing ownership stakes from being diluted but increases the company’s fixed obligations—like a household taking a fixed-rate mortgage instead of an option to buy the lender’s equity—and so affects cash flow, risk of default, and future returns.

equity dilution financial

"minimizing equity dilution for existing shareholders."

Equity dilution happens when a company issues more shares, so each existing shareholder owns a smaller slice of the company; think of slicing the same pizza into more pieces. It matters to investors because dilution can reduce an individual’s voting power and share of future profits or earnings per share, potentially lowering the market value of existing holdings unless the new capital meaningfully increases the company’s overall worth.

credit facility financial

"does not represent an established, committed or currently available credit facility."

A credit facility is a flexible loan arrangement that allows a borrower to access funds up to a set limit whenever needed, similar to a company having an overdraft option on a bank account. It matters to investors because it indicates how easily a business can secure cash when required, affecting its ability to manage expenses, invest, or respond to financial challenges.

due diligence financial

"subject to lender approval, satisfactory due diligence, definitive documentation"

Due diligence is the careful investigation and analysis someone conducts before making a decision, such as investing money or entering into an agreement. It’s like researching thoroughly before buying a used car to ensure it’s in good condition; this helps prevent surprises and makes informed choices. For investors, due diligence reduces risk by verifying details and understanding what they’re getting into.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Financial advisory appointment to support planned acquisitions of profitable, revenue-generating businesses during 2027

DUBLIN, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “Company”), a developer of non-invasive health monitoring technologies, announces that it has entered into a non-exclusive financial advisory agreement with Vienna Capital Partners LLC (“Vienna Capital”), a New York-based financial services firm, to support its proposed US$100 million-plus acquisition financing strategy for 2027.

The appointment forms part of Davion’s strategy to build a diversified healthcare and related services group through the acquisition of established, profitable and cash-generative businesses, principally in the United States. It follows the Company’s recent announcement of its proposed $13.5 million acquisition of Healthcare Stat Homecare Inc., a profitable US home healthcare business.

Under the agreement, Vienna Capital will advise Davion on institutional financing structures and potential funding arrangements to support its acquisition program. The Company intends to focus principally on senior secured, non-convertible debt financing from institutional lenders, private credit providers and other financial institutions, with the objective of supporting acquisitions while minimizing equity dilution for existing shareholders.

Davion has established an initial aggregate financing objective of US$100 million, with the potential to increase this as its acquisition program develops.

The proposed financing is intended to support multiple acquisitions rather than a single transaction, with opportunities assessed according to their profitability, cash generation, asset backing and strategic contribution to the Group.

The Company will focus on established businesses with proven operating histories, sustainable revenues and positive cash flow. Financing arrangements are expected to be evaluated on a transaction-by-transaction basis and may be undertaken through Davion’s US subsidiary, Davion Healthcare Corp, or designated acquisition vehicles.

Glenn Williams, Chief Executive Officer of Davion, commented:

“Our strategy is to build a substantial healthcare and related services group by combining our proprietary technologies with established, profitable businesses that bring revenues, earnings and operational capabilities. The appointment of Vienna Capital is an important step in developing the financing arrangements to support that ambition. Our initial US$100 million financing objective reflects the scale of the acquisition opportunities we intend to pursue during 2027, and our preference is to use institutional debt wherever commercially appropriate, allowing us to expand while limiting dilution for existing shareholders. We look forward to working with Vienna Capital as we progress our acquisition program.”

Dr Vincent deFilippo, Chief Executive Officer of Vienna Capital Partners LLC, added:

“Davion has an exciting opportunity to combine innovative healthcare technologies with established, profitable businesses to build a diversified healthcare group. We believe its acquisition strategy offers a compelling platform for long-term growth, and we are pleased to support the Company in evaluating institutional financing opportunities and developing the financial structures needed to pursue its ambitions.”

Financing Arrangements

Vienna Capital will work with Davion to evaluate potential financing structures, institutional lending markets and funding alternatives appropriate to individual acquisitions.

The Company anticipates that financing arrangements, if successfully negotiated, will be tailored to individual transactions and may be implemented progressively throughout 2027.

Davion’s initial US$100 million financing objective is an indicative aggregate target and does not represent an established, committed or currently available credit facility. No binding lender commitments have been secured under the proposed program.

Any future financing will be subject to lender approval, satisfactory due diligence, definitive documentation and applicable conditions. There can be no assurance that financing will be obtained in any particular amount or on acceptable terms, or that any proposed acquisition will be completed.

The Company will provide further updates as appropriate.

Media Inquiries

Rosewood Communications
+44 (0) 20 7653 8702
davion@rosewoodpr.co.uk

Investor Relations Inquiries

Mark Komonoski
Partner
Integrous Communications
Toll Free: 877-255-8483
Mobile: 403-470-8384
mkomonoski@integcom.us

About Davion Healthcare Plc

Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.

The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare.

Davion’s growth strategy combines the development and commercialization of its proprietary technologies with complementary acquisitions intended to expand the Group’s revenues, earnings, operating capabilities and presence in healthcare and related services markets.

Further information is available at www.davionhealthcare.com.

About Vienna Capital Partners LLC

Vienna Capital Partners LLC is a New York-based, FINRA-registered financial services firm and family office specializing in strategic capital solutions, investment banking advisory and management consulting services for private and publicly traded companies.

The firm advises on financing structures, mergers and acquisitions and corporate growth strategies, with activities spanning sectors including healthcare, energy, consumer products, private credit, logistics and technology infrastructure.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions.

The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.

Numerous factors could cause or contribute to such differences, including, but not limited to, the availability and terms of acquisition financing, the Company’s ability to identify, negotiate and complete suitable acquisitions, the financial performance of acquired businesses, the integration of acquired operations, the results of product evaluations, studies, regulatory reviews and commercial adoption, the challenges inherent in new product development initiatives, the impact of competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, except as required by applicable law.

The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Davion Healthcare’s acquisition financing target for 2027?

Davion’s initial aggregate financing objective is US$100 million, with potential to increase as its acquisition program develops. The proposed financing would support multiple acquisitions rather than a single transaction. The target is indicative and does not represent an established, committed or currently available credit facility.

Has Davion Healthcare secured financing commitments for its acquisition program?

No binding lender commitments have been secured under the proposed program. Any future financing remains subject to lender approval, satisfactory due diligence, definitive documentation and applicable conditions.

How does Davion Healthcare expect to arrange acquisition financing during 2027?

Davion expects to evaluate financing transaction by transaction and, if successfully negotiated, implement arrangements progressively throughout 2027. Financing may be undertaken through its US subsidiary, Davion Healthcare Corp, or designated acquisition vehicles.